Last reviewed · How we verify
ROTAVAC 5C -F1 — Competitive Intelligence Brief
phase 3
Live attenuated rotavirus vaccine
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
ROTAVAC 5C -F1 (ROTAVAC 5C -F1) — Bharat Biotech International Limited. ROTAVAC 5C-F1 is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ROTAVAC 5C -F1 TARGET | ROTAVAC 5C -F1 | Bharat Biotech International Limited | phase 3 | Live attenuated rotavirus vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Live attenuated rotavirus vaccine class)
- Bharat Biotech International Limited · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ROTAVAC 5C -F1 CI watch — RSS
- ROTAVAC 5C -F1 CI watch — Atom
- ROTAVAC 5C -F1 CI watch — JSON
- ROTAVAC 5C -F1 alone — RSS
- Whole Live attenuated rotavirus vaccine class — RSS
Cite this brief
Drug Landscape (2026). ROTAVAC 5C -F1 — Competitive Intelligence Brief. https://druglandscape.com/ci/rotavac-5c-f1. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab